FDA targets online ketamine sellers as health premiums surge, and children 2+ can now obtain CGMs without prescription

The Food and Drug Administration is intensifying its enforcement against online retailers that sell ketamine, a controlled substance, citing concerns about unregulated distribution and public safety.

At the same time, the agency highlighted a wave of unprecedented health‑care premium increases that could affect a broad range of consumers and insurers, signaling pressure on the overall cost landscape.

In a separate development, the FDA cleared Dexcom’s continuous glucose monitor for use by children aged two and older without requiring a physician’s prescription, expanding access to this technology for families managing pediatric diabetes.